

PRESS RELEASE



For Immediate Release

Contact: info@globalcancertechnology.com

Global Cancer Technology's GCT-007 receives promising pre-clinical results from the Baylor College of Medicine

Results show a significant and reproducible survival benefit using GCT-007 in a native mouse model of GBM

San Diego, CA, June 27, 2024—Global Cancer Technology (GCT) is pleased to announce promising pre-clinical results with its novel and proprietary PI3 Kinase inhibitor, GCT-007, a small molecule PI3Kinase inhibitor, in a mouse model of glioblastoma studied by researchers at the Baylor College of Medicine in Houston, Texas. The team, under the direction of the principal investigator and neurosurgeon Dr. Ali Jalali, performed *in vivo* animal studies by treating 4- or 8-week-old GBM mice orally with GCT-007. The treatments significantly and reproducibly prolonged the survival of tumor-bearing mice when compared to placebo. The team also has preliminary evidence that combination with anti-PD1 treatment may augment the effectiveness of checkpoint inhibitor immunotherapy.

“We are delighted to see improved survival in this pre-clinical study of GBM and look forward to extending these results in additional studies,” said Dr. Ali Jalali.

John Clark, the CEO of Global Cancer Technology, further added: “This is yet another confirmation of the benefits of GCT-007 as well as potential benefits when combined with other treatments such as checkpoint inhibitors, yielding impressive pre-clinical data in glioblastoma studies.”

Global Cancer Technology is a pre-clinical non-revenue biopharma company that is currently raising investment capital to enter a Phase 1 clinical trial (globalcancertechnology.com). Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent shareholder letter. There is no assurance that any new products will be cleared for sale by the FDA or successfully commercialized.